Autologous antibodies to human bladder cancer by Stein, Judith et al.
Cancer Immunol Immunother (1988) 26:269-272   ancer mmunol9gy 
mmunotherapy 
© Springer-Verlag 1988 
Autologous antibodies to human bladder cancer* 
H. Barton Grossman, Gary Wedemeyer, and Judith Stein 
Department of Surgery, Section of Urology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA 
Summary. The autologous serologic reactivity of  13 pa- 
tients with bladder cancer was evaluated using cell lines 
derived from each individual 's own tumor as targets. Pro- 
tein A and immune adherence assays were employed to 
determine antibody binding to the tumor targets at varying 
passage numbers. Autologous reactivity was found in 6 of  
the 13 cell lines tested. However, the titer was usually low 
regardless of  the passage number. Seven autologous se- 
rum/cel l  line combinations were tested using both low and 
high passage cells as targets. In six of  these combinations, 
the degree of  antibody binding was similar with both low 
and high passage target cells. The incidence of  autologous 
reactivity in the 12 patients with urothelial tumors was 
50%. 
Introduction 
The basis for immunotherapy rests in the belief that tumor- 
associated antigens can be defined that are different from 
those expressed on normal tissues. Prior to the modern era 
o f  murine and human monoclonal  antibodies, tumor-asso- 
ciated antigens were defined using polyclonal human sera 
in cellular and serologic assays [2, 9, 21]. These efforts 
strongly suggested that tumor-associated antigens do exist, 
and that in some cases the antigens are highly tumor-res- 
tricted [22]. Evidence for such conclusions were found in 
melanoma, leukemia, renal cancer, and other tumors [3, 8, 
20, 27]. The application of  monoclonal  antibody technolo- 
gy (primarily murine) has confirmed much of  this early da- 
ta. Monoclonal  antibodies have been defined which pref- 
erentially bind to a variety of  tumors including melanoma, 
leukemia, and carcinomas of  the bladder, breast, kidney, 
and lung [1, 6, 7, 18, 19, 23]. 
We have previously reported on the establishment of  
new human bladder cancer cell lines from our laboratory 
[12]. The availability of  these cell lines presented an oppor- 
tunity to evaluate the prevalence and degree (titer) o f  anti- 
body  production by patients to their own bladder cancer 
cell lines (autologous reactivity). An understanding of  au- 
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tologous reactivity to bladder cancer is of  practical impor- 
tance because it facilitates the rational selection of  poten- 
tial strategies for producing human monoclonal  antibodies 
to bladder tumor-associated antigens. 
Materials and methods 
The following cell lines have been previously reported: 
UM-UC-1,  UM-UC-2,  UM-UC-3,  UM-UC-6,  UM-UC-7,  
UM-UC-8,  and MELBA [10, 12]. UM-UC-9,  UM-UC-10, 
UM-UC-11, UM-UC-12, UM-UC-13, and UM-UC-14 are 
new human bladder carcinoma cell lines which have been 
established in our laboratory. A summary of  the character- 
istics of  these cell lines is listed in Table 1. The cell lines 
were maintained in Eagle's minimum essential medium 
supplemented with 1% nonessential amino acids, 2 m M  
L-glutamine, 100 u /ml  penicillin, 100 lxg/ml streptomycin, 
and 10% fetal bovine serum (FBS). Autologous serum from 
patients bearing the tumors from which these cell lines 
were established was obtained by venipuncture. The pa- 
tient's tumor stage at the time of  the blood collection var- 
ied widely: 3 patients had no evidence of  disease; 5 had 
advanced localized diseases; 4 had lymphatic metastases; 
and 1 had distant metastases. The serum was obtained by 
refrigerated centrifugation, divided into aliquots, and 
stored at - 7 0 ° C  until used. Serologic assays were per- 
formed at several different passages of  the autologous 
cells. 
Table 1. New bladder (urothelial) cell lines 
Cell line Histology Highest Growth in 
passage nude mouse 
UM-UC-1 Transitional cell 
UM-UC-2 Transitional cell 
UM-UC-3 Transitional cell 
UM-UC-6 Transitional cell 
UM-UC-7 Transitional cell 
UM-UC-8 Transitional cell 
UM-UC-9 Transitional cell 
UM-UC-10 Transitional cell 
UM-UC-11 Transitionalcell 
UM-UC-12 Transitional cell 
UM-UC-13 Transitional cell 




























Table 2. Autologous typing of bladder carcinomas 
Cell line Immune adherence assay a 
0-10  11-20 21-30 >30 
Protein A assay" 
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a Reciprocal oftiter by passage number 
0 signifies no reactivity with undiluted serum 
Table 3. Summary of autologous typing of bladder carcinomas 
Cell line Immune adherence assay Protein A assay 
Low High Low High 
passage a passage b passage passage 
UM-UC-1 1 1 1 2 
UM-UC-2 NT 0 2 0 
UM-UC-3 0 0 128 0 
UM-UC-6" 0 0 0 0 
UM-UC-7 0 0 0 0 
UM-UC-8 0 NT 1 NT 
UM-UC-9 NT 2 NT 0 
UM-UC-10 0 0 0 2 
UM-UC-11 NT 0 NT 0 
UM-UC-12 NT 0 NT 0 
UM-UC-13 NT 0 NT 0 
UM-UC-14 NT 0 NT 0 
MELBA 0 0 0 0 
NT = Not tested 
0 = Signifies no reactivity 
passage 20 or earlier 
b passage 21 or later 
with undiluted serum 
The assays used for  the analysis  were the immune  ad- 
herence (IA) assay and the prote in  A (PA) assay, and  were 
per formed  as previously  descr ibed [11]. In  brief,  autolo-  
gous target  cells were t rypsinized,  washed,  and  p la ted  into 
microtest  plates at a concentra t ion  of  200 cel ls /wel l  
(10 lxl). Phosphate-buffered saline with 5% g a m m a  globu- 
l in-free FBS (PBS) was used for di lut ing the an t ibody  and 
washing the plates.  On the day  of  the assay, the microt i ter  
wells conta in ing target  cells were washed and incubated  
with 10 Ixl of  serially di luted an t ibody  or  control  (PBS). In 
the I A  assay, the plates were incubated  at 4 ° C  for 1 h, 
washed,  and incubated  with indica tor  cells (0.5% human  0 
erythrocytes with di luted guinea pig serum as a source of  
complement)  for 30 min at 37 ° C. In the PA assay, the anti- 
body  incubat ion was pe r fo rmed  at room temperature ,  and  
the indica tor  cells (human 0 erythrocytes coupled  to sta- 
phylococca l  pro te in  A using chromium chloride)  were in- 
cubated for 45 rain at room temperature.  In  both assays, 
the plates  were again washed after the indica tor  cell incu- 
bat ion,  and  posit ive react ions (rosettes of  erythrocytes 
a round  the target cells) were determined microscopical ly .  
Results were expressed as the percentage of  posit ive cells 
in each well. 
Positive controls  included rabbi t  ant i -beta-2-micro-  
globul in for the PA assay and human  ant i -A and anti-B 
b lood  typing sera for the IA  assay. With  few exceptions,  
repl icate  assays were per formed  on the same or  different  
days. A posit ive ti ter was def ined as the highest di lut ion 
having 20% posit ive cells per  well. 
R e s u l t s  
The autologous reactivity by  passage and assay methods  is 
l isted in Table 2. There was little var iabi l i ty  between assays 
for target cells of  the same passage number  whether  tested 
on the same or different  days. Four  assay pairs  (repeat as- 
says using the same passage number  target cell) differed by 
one doubl ing di lut ion,  two assay pairs  differed by two 
doubl ing  dilut ions,  and only one series of  assays (three 
tests of  the same passage number  target cell) differed by 
more  than two doubl ing dilutions.  
Autologous  reactivi ty was found in 6 of  the 13 cell 
lines tested. However ,  the titer was usually low regardless 
o f  the passage number.  There was no correlat ion between 
tumor  stage and autologous reactivity. Seven cell lines 
were tested both at low and high (greater than 20) passages 
(Table 3). Only one o f  these demons t ra ted  a large change 
in autologous reactivi ty (greater than 2 doubl ing  dilut ions) 
over  time. Autologous  serum to UM-UC-3 target cells pro-  
duced titers of  1/128 in the PA assay at passages 10 and 
11. At passages 21, 22, and  40, the titer was only 1/2. 
There was no autologous reactivi ty at passage 64. The re- 
mainder  of  the cell lines showed little or  no change with 
passage in vitro. Two of  the cell lines were tested at very 
low passage numbers  (3 or earlier). UM-UC-2  was tested 
at passage 1 with the PA assay. UM-UC-3 was tested at 
passage 3 with the IA assay. Autologous  targets tested at 
very early passage number  did  not  demonst ra te  significant 
changes in an t ibody  titer with extended t ime in culture. 
D i s c u s s i o n  
Some individuals  with cancer  demonst ra te  an immune re- 
sponse to their own neoplasms by generat ing ant ibodies  
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that have high specificity for their tumor [22]. Because se- 
rum contains multiple antibodies with different specifici- 
ties, the detection of  antibodies to tumor-associated anti- 
gens can be facilitated by employing autologous tumor 
cells as targets. The use of  autologous tumor cell targets 
eliminates potential errors from antibody binding to non- 
tumor-associated alloantigens. Employing such a strategy, 
tumor-associated antibodies have been detected in patients 
with melanoma, leukemia, sarcomas, and cancer of  the 
brain, breast, kidney, and ovary [3, 8, 16, 17, 20, 25, 27]. 
The existence of  autologous reactivity to tumor-associated 
antigens has relevance to the development of  appropriate 
strategies for the application of  monoclonal  antibody tech- 
nology to human lymphocytes. For example, if lympho- 
cytes producing antibodies to tumor-associated antigens 
were both common and abundant,  then peripheral blood 
lymphocytes could be randomly obtained from patients 
with cancer and be used to produce human monoclonal  
antibodies to tumor-associated antigens. On the other 
hand, should peripheral blood lymphocytes not be an effi- 
cient source of  cells producing antibody to tumor-associat- 
ed antigens, then a more productive strategy would be to 
utilize a lymphocyte selection process a n d / o r  immuniza- 
tion (in vitro or in vivo) to increase the number  of  lympho- 
cytes producing antibody to tumor-associated antigens. 
Human monoclonal  antibodies have potential advantages 
over murine monoclonal  antibodies because of  the docu- 
mented antigenicity of  murine antibodies in man [24]. 
We evaluated autologous reactivity using cell lines de- 
rived from an individual 's own tumor as targets. Two sen- 
sitive assays were employed to determine antibody binding 
to cell surface antigens on the tumor targets at varying pas- 
sage numbers. Autologous reactivity was found in 6 of  the 
13 cell lines tested. However, the titer was usually low. The 
degree of  antibody binding was similar using both low and 
high passage cells as targets. Although clonal selection is 
always a potential problem when employing cell lines in- 
stead of  fresh tumor, the consistency in the degree of  au- 
tologous reactivity using low and high passage target cells 
suggests that the quantity and quality of  the observed reac- 
tivity cannot simply be attributed to an artifact of  tissue 
culture. 
Our incidence o f  autologous reactivity in the 12 pa- 
tients with urothelial tumors was 50%. The serum from an 
additional person with melanoma of  the bladder demon- 
strated no autologous reactivity. This incidence of  autolo- 
gous reactivity is similar to that reported in people with 
other types of  malignant tumors: leukemia (14%) [8], gli- 
oma (50%) [5], ductal breast carcinoma (55%) [25], squamous 
cell carcinoma (56%) [4], melanoma (56%) [26], astrocyto- 
ma (100%) [20], and renal carcinoma (100%) [27]. The vary- 
ing incidence of  autologous reactivity in these reports may 
not only reflect different degrees of  antigenicity of  these 
histologically diverse tumor types but also the sensitivity 
of  the numerous assays employed. Although all autologous 
reactivity is by definition tumor-associated, not all autolo- 
gous reactivity is tumor-specific [20]. The determination of  
specificity requires high titer antibody that may be further 
analyzed by serologic absorption and other techniques [20, 
22]. The low antibody titers that we observed precluded 
further characterization o f  the specificity (range of  reactiv- 
ity) of  the binding by serologic absorption. Our finding of  
a moderate to high frequency of  autologous tumor-asso- 
ciated antibodies with low titer has been a recurring obser- 
vation in the tumor systems that have been evaluated. Fur- 
thermore, when rigorous absorption studies have been per- 
formed, many of  these antibodies bind to antigens that are 
widely distributed through both normal and neoplastic cell 
populations. 
A variety of  sensitive assays have detected a high inci- 
dence of  autologous antibody in people with diverse mal- 
ignancies. However, the underlying immune response ap- 
pears to be weak (antibodies of  low titer) and nonspecific 
(not tumor-restricted) in most patients. These findings sug- 
gest that the routine use of  peripheral lymphocytes from 
tumor-bearing patients is not  an efficient strategy for the 
production of  human monoclonal  antibodies to tumor-as- 
sociated antigens. Alternative strategies with documented 
efficacy include lymphocyte selection (lymphocytes from 
regional lymph nodes) [15] and immunization (both in vit- 
ro and in vivo) prior to fusion [13, 14]. 
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